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Abstract: Western equine encephalitis virus (WEEV) causes symptoms in humans ranging from
mild febrile illness to life-threatening encephalitis, and no human medical countermeasures are
licensed. A previous study demonstrated that immune serum from vaccinated mice protected
against lethal WEEV infection, suggesting the utility of antibodies for pre- and post-exposure
treatment. Here, three neutralizing and one binding human-like monoclonal antibodies were
evaluated against WEEV aerosol challenge. Dose-dependent protection was observed with two
antibodies administered individually, ToR69-3A2 and ToR68-2C3. In vitro neutralization was not a
critical factor for protection in this murine model, as ToR69-3A2 is a strong neutralizing antibody, and
ToR68-2C3 is a non-neutralizing antibody. This result highlights the importance of both neutralizing
and non-neutralizing antibodies in the protection of mice from WEEV lethality.
Keywords: western equine encephalitis virus (WEEV); alphavirus; monoclonal antibody (mAb);
scFv-Fc; NHP antibodies; passive vaccine; aerosol challenge; antibody engineering
1. Introduction
The single-stranded positive-sense RNA virus, western equine encephalitis virus (WEEV),
is a member of the Togaviridae family [1]. WEEV is a natural chimera resulting from the recombination
of eastern equine encephalitis virus (EEEV) and Sindbis virus (SINV) [2]. In humans, WEEV, EEEV
and Venezuelan equine encephalitis virus (VEEV) cause disease symptoms ranging from a mild
febrile illness to severe encephalitis that may lead to mortality [1]. Disease severity is influenced
by multiple factors including viral strain, dose and route of inoculation, as well as health status
and age of the patient [1,3–5]. WEEV has caused sporadic outbreaks in horses and humans [6–8].
Most recently, an outbreak in Uruguay in 2009 resulted in a fatal human case [9]. Disease severity
coupled with the ease of production and dissemination of the encephalitic alphaviruses has resulted
in these agents designated as Category B pathogens and highlights the need to develop effective
medical countermeasures in the event of a biological attack. Other arboviruses, such as chikungunya
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and Zika virus, have demonstrated rapid shifts in disease prevalence causing widespread epidemics,
demonstrating the importance of preparation for potentially emerging infectious diseases.
The pursuit for a vaccine that is safe and efficacious against alphavirus exposure has revealed
an essential role of antibodies in the control of virus infection [10–13]. Furthermore, the level
of neutralizing antibody response elicited by a vaccine candidate often determines its continued
development. Passive transfer of hyperimmune serum from WEEV-vaccinated animals into naïve
recipients was protective [13–15], making the use of antibody therapeutics attractive as a rapidly
deployable medical countermeasure. For this reason, monoclonal antibodies against other alphaviruses,
including VEEV [16] and Semliki Forest virus [17], have been under development since the 1980s.
Humanized murine [16,18], nonhuman primate (NHP) [19,20], as well as human [21] antibodies have
been developed as potential medical countermeasures.
Previously, four human-like antibodies were identified from immune antibody gene libraries
constructed from inactivated WEEV-vaccinated macaques [19]. While all four antibodies bound WEEV
antigen by ELISA, only three of the four had varying degrees of WEEV neutralizing activity in an
in vitro assay. Here, the ability of these four WEEV-specific monoclonal antibodies to protect mice
from a lethal WEEV aerosol exposure was examined.
2. Materials and Methods
2.1. Ethics Statement and Animal Care
Research was conducted under a USAMRIID Institute Animal Care and Use Committee-approved
protocol (9 May 2016) in compliance with the Animal Welfare Act, Public Health Service Policy,
and other Federal statutes and regulations relating to animals and experiments involving animals.
The USAMRIID is accredited by the Association for Assessment and Accreditation of Laboratory
Animal Care, International, and adheres to principles stated in the Guide for the Care and Use of
Laboratory Animals, National Research Council, 2011.
2.2. Antibody Preparation
The antibodies ToR68-2C3, ToR68-2E9, ToR68-3G2 and ToR69-3A2 were produced as scFv-Fc with
a human Fc part as described previously [22].
2.3. Virus Stock
The WEEV Fleming stock was obtained from the World Reference Center for Emerging Viruses
and Arboviruses (Galveston, TX). The stock was amplified three times in Vero cells from a lyophilized
stock that had undergone five passages through suckling mouse brain.
2.4. In Vivo WEEV Challenge
Specific pathogen-free, eight-week-old BALB/c mice (n = 10/group; Charles River Laboratories)
were utilized as a model for WEEV infection. Mice received a single inoculation of monoclonal
antibody, irrelevant anti-Marburg virus (100 µg) antibody [23] or PBS intraperitoneally approximately
24 h prior to challenge. Based on previous LD50 studies, mice were exposed to a target inhaled dose of
1 × 103 PFU by the aerosol route using the Automated Bioaerosol Exposure System (ABES) II, inside
a Class III biological safety cabinet. All mice were weighed on Days 1–14 after challenge and were
monitored daily throughout the study for clinical signs of disease.
3. Results
WEEV mAb Prophylaxis in Mice
ToR68-2C3, ToR68-2E9, ToR68-3G2 and ToR69-3A2 were previously identified to have WEEV
binding activity [19]. Additionally, ToR68-2E9, ToR68-3G2 and ToR69-3A2 neutralized WEEV,
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while ToR68-2C3 did not [19]. To examine the ability of these mAbs to protect mice from WEEV
exposure, BALB/c mice (n = 10/group) were administered a single-dose of decreasing concentrations
(200 µg–10 µg per mouse) of the mAbs by the intraperitoneal (i.p.) route. Approximately 24 h after
mAb administration, mice were exposed by the aerosol route to a target inhaled dose of 1 × 103 PFU of
the WEEV Fleming strain [24]. Mice were monitored for clinical signs of disease and were euthanized
when moribund. As expected, an aerosol challenge with WEEV Fleming resulted in rapid weight loss
(Figure 1A) and disease progression with signs of neurological disease including hyper-reactivity and
circling (Figure 1B). By five days post-exposure, 100% lethality was observed with an average survival
time of four days for mice administered PBS or irrelevant mAb (Figure 2). Two of the neutralizing mAbs,
ToR68-3G2 and ToR68-2E9 provided no significant protection from the lethal WEEV aerosol exposure
with an average survival time (AST) of four days for all dose groups (Figure 2A,B). A dose-dependent
increase in survival was observed for the neutralizing ToR69-3A2 mAb with a 90% survival rate at
the 200-µg dose and a 50% survival rate at the lowest dose (10 µg; Figure 2C). Somewhat surprisingly,
treatment with the non-neutralizing Tor68-2C3 mAb resulted in 60% survival at the highest dose tested
(Figure 2D), and the level of protection observed with this non-neutralizing mAb was dose-dependent.
Both ToR69-3A2 and ToR68-2C3 reduced or eliminated clinical signs of disease (Figure 1B).
Figure 1. Morbidity of mice treated with anti-western equine encephalitis virus (WEEV) monoclonal
antibodies following WEEV exposure. (A) Cohorts of 10 mice were administered 200 µg/mouse of
ToR68-2E9 (purple), ToR68-2C3 (blue), ToR69-3A2 (green), Tor68-3G2 (orange), irrelevant anti-Marburg
virus (100 µg/mouse; solid red) mAb per mouse or an equivalent volume of PBS (dashed red) mAb i.p.
24 h prior to aerosol exposure to WEEV Fleming (103 PFU). Mice were weighed daily, and the percent
weight loss was determined by comparison to pre-challenge day weights. (B) Clinical observations
were made twice daily. Mice were moribund when displaying neurological signs of disease or were
unresponsive to stimulus. Data shown are the clinical signs observed on Day 4 (average survival
day) post-exposure.
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Figure 2. Mortality of mice treated with anti-WEEV monoclonal antibodies following WEEV exposure.
(A) Mice administered ToR68-3G2. (B) Mice administered ToR68-2E9. (C) Mice administered ToR69-3A2.
(D) Mice administered ToR68-2C3. Cohorts of 10 mice were administered 200 µg (purple), 100 µg
(blue), 25 µg (green), 10 µg (orange) mAb per mouse, 100 µg irrelevant anti-Marburg virus (solid red)
mAb per mouse or an equivalent volume of PBS (dashed red) i.p. 24 h prior to aerosol exposure to
WEEV Fleming (103 PFU). Mice were observed twice daily for clinical signs of disease and humanely
euthanized when moribund.
4. Discussion
Anti-WEEV immune serum from rabbits [23], mice [14] and NHPs [25] passively administered
to mice can protect against lethal WEE disease. However, to date, no neutralizing or protective
murine, human or human-like anti-WEEV monoclonal antibodies have been identified [26]. Here,
we demonstrated the first use of a monoclonal antibody prophylaxis to protect mice challenged by
a lethal WEEV aerosol exposure. Importantly, protection was observed with a single dose of either
a neutralizing antibody ToR69-3A2 or a non-neutralizing antibody ToR68-2C3. Non-neutralizing
monoclonal antibodies have demonstrated some success in mouse protection studies against other
alphaviruses, including Sindbis virus [27], Semliki Forest virus [17] and VEEV [20,28]. The mechanism
of action of ToR68-2C3 is undefined, but protection may be attributed to complement-mediated lysis
or antibody-dependent cell-mediated lysis of infected cells [29,30]. Together, these data highlight the
importance of in vivo evaluation of both neutralizing and non-neutralizing monoclonal antibodies for
protective efficacy.
Despite efforts in antibody identification against alphaviruses, this is the first report of a
monoclonal antibody that protected mice against a WEEV challenge. In vaccination studies delivering
WEEV, EEEV and VEEV antigen concomitantly, WEEV antigens appear to be less immunogenic
in comparison to VEEV and EEEV antigens. This is evidenced by lower neutralizing and binding
antibody titers to WEEV vaccine components when similar protein concentrations are delivered
in a trivalent formulation [25,31]. Alternatively, the reduced immunogenicity of WEEV antigen
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in these studies may be a result of immunologic interference similar to what was observed in
humans after sequential alphavirus vaccine administration [32,33]. Despite the potential lower
WEEV immunogenicity, the vaccines tested protected 100% of mice, suggesting the combination
of neutralizing and binding antibodies could be important to confer protection. In comparison to
the other encephalitic alphaviruses, WEEV’s reduced protein immunogenicity may contribute to the
difficulty of identifying a single WEEV monoclonal antibody that is completely protective.
Neither antibody provided 100% protection from lethality after WEEV aerosol exposure even
at the 200 µg dose. Studies with passive administration of immune serum from NHPs [25,34] and
transchromosomic bovine IgG [35] into mice have found that a single administration was not 100%
protective against a high dose aerosol exposure of VEEV [35], EEEV or WEEV [25,34]; however,
delivery of a second administration resulted in 90–100% survival. This would suggest that a second
administration of ToR69-3A2 or ToR68-2C3 may result in enhanced survival. Another possibility is the
generation of antibody-escape mutants, which have been identified for other viruses including Ebola
virus [36], Dengue virus [37] and influenza virus [38], as well as alphaviruses [39,40]. Therefore, future
studies will evaluate this possibility and also the efficacy of a cocktail of ToR69-3A2 and ToR68-2C3 for
enhanced survival benefits.
To summarize, this manuscript describes the first monoclonal antibodies that are protective
against WEEV in a mouse in vivo aerosol challenge model.
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